title: Transgenic CCL2 expression in the central nervous system results in a dysregulated immune response and enhanced lethality after coronavirus infection.
abstract: Chemokine (C-C motif) ligand 2 (CCL2), a chemoattractant for macrophages, T cells, and cells expressing CCR2, is upregulated during acute and chronic inflammation. CCL2 has been implicated in both proinflammatory and anti-inflammatory responses and has been suggested as a target for therapy in some inflammatory disorders. To examine the role of CCL2 during virus infection, we infected mice transgenically expressing CCL2 in the central nervous system (CCL2 Tg) with an attenuated neurotropic coronavirus (rJ2.2 strain of mouse hepatitis virus). Infection of wild-type mice with rJ2.2 results in mild acute encephalitis, followed by a nonlethal, chronic demyelinating disease. Proinflammatory innate and adaptive immune responses mediate virus clearance. In marked contrast, CCL2 Tg mice infected with rJ2.2 ineffectively cleared virus and rapidly succumbed to the infection. CCL2 Tg mice mounted a dysregulated immune response, characterized by augmented accumulation of regulatory Foxp3(+)CD4(+) T cells and of nitric-oxide- and YM-1-expressing macrophages and microglia, suggestive of mixed M1/M2 macrophage activation. Further, macrophages from infected CCL2 Tg brains relative to non-Tg controls were less activated/mature, expressing lower levels of major histocompatibility complex class II (MHC-II), CD86, and CD40. Collectively, these results show that persistent CCL2 overexpression establishes and sustains an immunological milieu that is both inflammatory and immunosuppressive and predisposes mice to a defective immune response to a minimally lethal virus.
authors.affiliation: Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, Iowa, USA.
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Trujillo
authors.forename: Erica L
authors.initials: EL
authors.lastname: Fleming
authors.forename: Stanley
authors.initials: S
authors.lastname: Perlman
mesh_terms: D000818:Animals; D051940:B7-2 Antigen / Q000096:biosynthesis; D001921:Brain / Q000276:immunology* / Q000378:metabolism / Q000821:virology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019013:CD40 Antigens / Q000096:biosynthesis; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism*; D018352:Coronavirus Infections / Q000276:immunology* / Q000401:mortality / Q000821:virology; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000096:biosynthesis; D051858:Forkhead Transcription Factors / Q000096:biosynthesis; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology; D007165:Immunosuppression Therapy; D007249:Inflammation / Q000276:immunology* / Q000378:metabolism; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D017628:Microglia / Q000276:immunology / Q000378:metabolism; D006517:Murine hepatitis virus / Q000276:immunology; D009569:Nitric Oxide / Q000096:biosynthesis
chemical_list: D051940:B7-2 Antigen; D019013:CD40 Antigens; C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D051858:Forkhead Transcription Factors; C498833:Foxp3 protein, mouse; D000949:Histocompatibility Antigens Class II; C079109:N-(3-pyridylmethyl)adriamycin; D009569:Nitric Oxide; D004317:Doxorubicin